Timothy Springer
$1.5B
as of 10/04/24
About Timothy Springer
Timothy Springer is an immunologist and professor of biological chemistry and molecular pharmacology at Harvard Medical School.
He was a founding investor in publicly traded biotech outfit Moderna in 2010, investing about $5 million; he now owns 2.7% of the firm's shares.
Springer also owns shares in three smaller publicly traded biotech firms: Cartesian Therapeutics, Scholar Rock and Morphic Therapeutic.
He first started teaching at Harvard in 1977 as an assistant professor.
In 1993, he founded biotech firm LeukoSite and took it public in 1998; the next year, he sold it to Millennium Therapeutics for $635 million.
Personal stats
Citizenship
United States of AmericaSource of wealth
BiotechResidence
Chestnut Hill, MassachusettsMarital status
MarriedBirth date
02/23/48 (age 76)Education
Ph.D, Harvard University; Bachelor of Science, University of California, BerkeleySelf-made
self-madeTimothy Springer’s fortune is worth
25K
troy ounces of gold
23K
median U.S. household
15K
median U.S. income
0.03%
U.S. credit card volume
0.006%
GDP of the United States
0.004%
United States debt
Net worth history
Annual ranking
Related people
Did you know?
In 2017, Springer established the Institute for Protein Innovation, an independent nonprofit focused on researching proteins, with an initial grant of $10 million.
Net worth over time
Real-time ranking
Financial assets
NASDAQ | RNAC-US
Cartesian TherapeuticsNASDAQ | RNAC-US
Cartesian TherapeuticsNASDAQ | RNAC-US
Cartesian TherapeuticsNASDAQ | RNAC-US
Cartesian TherapeuticsNASDAQ | MRNA-US
Moderna, Inc.NASDAQ | MORF-US
Morphic HoldingNASDAQ | MORF-US
Morphic HoldingNASDAQ | SRRK-US
Scholar Rock Holding CorpNASDAQ | TECX-US
Tectonic TherapeuticImages © Forbes.com. All rights reserved.